Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02262741 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
NCT02262741 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 71 participants.
The verdict
NCT02262741, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with recurrent/metastatic squamous cell carcinoma of the head and neck.
Interventions
- BIOLOGICAL MEDI4736
- BIOLOGICAL tremelimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2014-10-15 |
| Est. Completion | 2017-09-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02262741
The ClinicalTrials.gov registry entry for NCT02262741 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MEDI4736 is the first listed.
NCT02262741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02262741 about?
NCT02262741 is a clinical study titled "A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer". This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with recurrent/metastatic squamous cell carcinoma of the head and n...
What is the current status of trial NCT02262741?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2014-10-15. Estimated completion is 2017-09-21.
What interventions are being tested in trial NCT02262741?
The interventions under investigation include: MEDI4736 (BIOLOGICAL), tremelimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02262741?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.